Insights · GPS Weekly
Who shapes what AI says about oncology
GPS Weekly · Issue 2 · 9 November 2026 · Signal Fidelity Group
Ask a search-grounded AI assistant four basic cancer questions: of the 40 sources it reads, the top ones are PubMed Central, GoodRx, a patient foundation's 2022 video and a 2018 CDC page kept in the National Archives.
- No guideline body holds any of the 40 sources. The top screening source is a retired CDC page that still says to start at 50.
- No oncology manufacturer's own site appears. Keytruda's price reaches the Medicare answer through GoodRx and Healthline.
- Few experts are named. HER2 rests on papers from 2012 to 2022 and CAR-T on one doctor's video. On cost, the bylines are writers and nurses, reviewed by doctors and pharmacists.
The who's who, ranked by share of the answer
| # | Who | The people on the page | Where they show up | Why it matters to comms | How to engage |
|---|---|---|---|---|---|
| 1 | PubMed Central (NIH journal archive) | De Mattos-Arruda and Cortes, Vall d'Hebron (2012); Lambertini … Del Mastro (2015); Zhang … Sun, Peking Union Medical College Hospital (2021); Nader-Marta, Martins-Branco, de Azambuja, Institut Jules Bordet (2022) | HER2: ranks 1, 2, 4, 8 ; CAR-T rank 6. Every run since August. | The top paper calls trastuzumab plus chemotherapy "the current standard of care" (2012). The 2021 and 2022 papers name THP. None of these papers is newer than January 2022. | Publication planning: open access gets read. |
| 2 | GoodRx (discounts, telehealth) | Mitzi S. Morris, reviewed by Karla Robinson, MD (31 Mar 2026); Roxanne Nelson, RN, BSN, reviewed by Patricia Pinto-Garcia, MD, MPH (19 Sep 2024) | Cost: ranks 1–3 (two articles). Also on four questions in other areas. | Sells "$19 online care visits"; prices Keytruda at $11,337.36 every 3 weeks as of March 2024, from keytruda.com. | Editorial desk. |
| 3 | HealthTree Foundation (patient organisation) | Sridevi Rajeeve, MD , video, 6 Sep 2022 | CAR-T: rank 1 . Also on the rare-disease specialist question. Every run since 11 October. | Leads CAR-T: "70 to 80% of them develop the early stage mild reactions." | Partnership; on no list. |
| 4 | National Archives copy of a CDC page | No author; CDC page last updated 20 Jun 2018 | Screening age: rank 1 . New this run. | "If you are age 50 to 75 years old, you should get screened." USPSTF moved to 45 in 2021. | Nothing to pitch; current guidance must outrank it. |
| 5 | HealthExec (trade) | Amy Baxter; quotes CMS Administrator Seema Verma and Acting FDA Commissioner Ned Sharpless, MD | Cost: ranks 5, 7, 10, one article dated 8 Aug 2019. Rank 1 on gene-therapy insurance. | A 2019 story prices CAR-T at "upwards of $500,000, according to one study." | Pitchable trade; on no list. |
| 6 | Healthline | Mary Sweeney, RN, BSN, CEN, ONN-CG-T, and Tess Catlett, reviewed by Oluwatoyin Kuloyo, Pharm.D., BCPS (2 Jun 2025); Eleesha Lockett, MS, reviewed by Alexandra Perez, PharmD, MBA, BCGP (12 May 2025) | Cost: ranks 6, 9. Every run since August. | "Keytruda infusions are covered by Medicare Part B as an outpatient prescription drug"; links keytruda.com. | On our oncology list. |
| 7 | Lymphoma Australia (patient charity) | No author printed | CAR-T: ranks 5 and 7 (the same page twice). | An Australian charity in a US answer. | Patient-organisation relationship. |
| 8 | MD Anderson | No author printed | CAR-T: rank 2. Every run since August. | The only cancer centre in the top five on CAR-T. | Health-system comms. |
Who shouldn't be there
None of the 40 sources is a demo, development or hijacked site this week. Two sit just outside: a CRM vendor's instance and an imaging vendor's demo site, ranks 17 and 18 on screening.
Who's missing
Absent: NCCN, ASCO, the American Cancer Society, USPSTF, any live FDA or CDC page, NEJM, JAMA and every oncology manufacturer. Of 30 outlet and channel domains on our oncology list, 27 are absent from all four questions, including STAT, Endpoints and The Cancer Letter. Only OncLive, the ASCO Post and Healthline appear.
What to do with it
- Brand and digital: GoodRx and Healthline answer Medicare with keytruda.com's numbers. Keep that page current and dated.
- Medical affairs: PubMed Central's HER2 papers stop at early 2022; a 2022 video leads CAR-T. Open, dated evidence gets read.
- Media relations: the journalists in this answer are HealthExec's Amy Baxter, OncLive and the ASCO Post.
How we measured it
Four frozen questions, one grounded web search each, run twelve times since August, most recently on 8 November; a 9 November re-run returned a different order on all four (on screening, colorectalcancer.org came first and the CDC copy second), so this issue ranks on 8 November. Every name was read on the page on 9 November; this shows what an assistant can read, not what one told a user.
The four questions: What is the best first-line treatment for HER2-positive metastatic breast cancer? · What are the side effects of CAR-T cell therapy? · How much does cancer immunotherapy cost and will Medicare cover it? · At what age should I start colorectal cancer screening?
Pages read: PMC, De Mattos-Arruda 2012 · PMC, Lambertini 2015 · PMC, Zhang 2021 · PMC, Nader-Marta 2022 · PMC, CAR-T table · GoodRx, Medicare · GoodRx, cost · GoodRx, biologics · HealthTree · National Archives, CDC screening · HealthExec · HealthExec, policy · HealthExec, healthcare policy · Healthline, immunotherapy · Healthline, Keytruda · Lymphoma Australia · Lymphoma Australia, alternate link · MD Anderson · Mesothelioma Hub (page not readable this week)
GPS is Signal Fidelity Group's map of who shapes what people and AI read about each therapy area.